These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15168796)

  • 1. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
    Zhang MY; Shu Y; Sidorov I; Dimitrov DS
    Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library.
    Zhang MY; Shu Y; Phogat S; Xiao X; Cham F; Bouma P; Choudhary A; Feng YR; Sanz I; Rybak S; Broder CC; Quinnan GV; Evans T; Dimitrov DS
    J Immunol Methods; 2003 Dec; 283(1-2):17-25. PubMed ID: 14659896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
    McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
    Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 10. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
    Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
    Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.
    Zhang MY; Shu Y; Rudolph D; Prabakaran P; Labrijn AF; Zwick MB; Lal RB; Dimitrov DS
    J Mol Biol; 2004 Jan; 335(1):209-19. PubMed ID: 14659751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.
    Jeffs SA; Goriup S; Kebble B; Crane D; Bolgiano B; Sattentau Q; Jones S; Holmes H
    Vaccine; 2004 Feb; 22(8):1032-46. PubMed ID: 15161081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
    Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
    Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
    [No Abstract]   [Full Text] [Related]  

  • 18. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
    Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
    Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.